4investors | Börsen-News | Adhoc- und Unternehmensnews | Biofrontera

DGAP-News: Biofrontera AG: Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results

Bild und Copyright: Michael Barck / www.4investors.de.

Bild und Copyright: Michael Barck / www.4investors.de.

16.05.2019, 10:30:02 (www.4investors.de - in Kooperation mit DGAP - EQS Group):

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous

Biofrontera AG: Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
16.05.2019 / 10:30

The issuer is solely responsible for the content of this announcement.
Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results Leverkusen, Germany, May 16, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock
Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its
financial results for the first quarter ended March 31, 2019 on May 29, 2019.

Conference calls for shareholders and interested investors will be held on May 29, 2019 at the following times:

In German, at 10:00 am CET (4:00 am ET)
Dial-in number Germany: +49 69201744220
Conference code: 87082878#

In English, at 2:00 pm CET (8:00 am ET)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 77726519#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.-End-

For enquiries, please contact:
Biofrontera AG
Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592
About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets AKTIPAK(R), a prescription medication for the treatment of acne, and Xepi(TM) for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

16.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Biofrontera AG

Hemmelrather Weg 201

51377 Leverkusen

+49 (0)214 87632 0
+49 (0)214 87632 90
DE0006046113, NASDAQ: BFRA
Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID:

End of News
DGAP News Service

812261  16.05.2019 

Weitere DGAP-News von Biofrontera

22.11.2019 - DGAP-News: Biofrontera AG: Biofrontera präsentiert demnächst auf mehreren Konferenzen
19.11.2019 - DGAP-Adhoc: Biofrontera AG: Biofrontera berichtet 9 Monateszahlen für 2019 und korrigiert Prognose
06.11.2019 - DGAP-News: Biofrontera AG: Telefonkonferenz der Biofrontera AG am 19. November 2019 anlässlich der Veröffentlichung der Quartalsmitteilung zum 30. September 2019
23.10.2019 - DGAP-News: Biofrontera AG: Biofrontera erhält Auszeichnung bei Fall Clinical Dermatology Conference 2019
10.10.2019 - DGAP-Adhoc: Biofrontera AG: ???????Biofrontera gibt vorläufige ungeprüfte Umsatzerlöse für die ersten neun Monate des Geschäftsjahrs 2019 bekannt

4investors-News zu Biofrontera

05.12.2019 - Biofrontera: Analyst senkt Kursziel für die Aktie
02.12.2019 - Biofrontera Aktie: Nach der Kurshalbierung nun die Erholungsrallye?
21.11.2019 - Biofrontera Aktie: Comeback oder nur eine Zwischenerholung?
19.11.2019 - Biofrontera verpasst Ziele - rote Zahlen für 2019 prognostiziert
17.10.2019 - Biofrontera Aktie: Neues Kursziel gesetzt